Concerning reports indicate the newly-approved Thyroid Eye Disease (TED) medication Tepezza could cause hearing loss and tinnitus. TED is the most common orbital disorder in adults, with a ...
Credit: Shutterstock. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. The Indications and Usage section of the Tepezza ® (teprotumumab-trbw) prescribing information has been ...
Physicians with questions should call or email Horizon Medical Information at 1-866-479-6742 or medicalinformation@horizontherapeutics.com. Additional TEPEZZA Information The Company continues to ...
-- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (AMGN) today announced TEPEZZA ® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...
For the first time, TED patients have a medicine that has been shown to significantly improve eye bulging and double vision, among other painful and debilitating symptoms TEPEZZA® (teprotumumab-trbw), ...
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "TEPEZZA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results